FIA
GYRE icon

FNY Investment Advisers’s Gyre Therapeutics GYRE Stock Holding History

FNY Investment Advisers’s Portfolio GYRE Stock Details GYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-533
Closed -$43K – 809
2018
Q3 		$43K Buy
533
+218
+69% +$17.3K 0.01% 380
2018
Q2 		$27K Buy
+315
New +$55.3K 0.01% 331

Other funds holding GYRE

NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
NC
Nexthera Capital New York $120M AUM 10.01% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
First Manhattan
First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

FNY Investment Advisers's GYRE Position: Q4 2018 in Review

FNY Investment Advisers sold out of Gyre Therapeutics (GYRE) in Q4 2018, closing a stake of 533 shares — an estimated $43K sold.

FNY Investment Advisers first reported a position in GYRE in Q2 2018 and held it in 2 quarters. The position peaked at $43K in Q3 2018. 65 funds tracked by Wall St. Rank hold GYRE as of Q4 2018.

  • FNY Investment Advisers reported no remaining Gyre Therapeutics position as of Q4 2018 after selling out during the quarter.
  • FNY Investment Advisers sold 533 Gyre Therapeutics shares in Q4 2018, an estimated $43K.
  • FNY Investment Advisers first reported a position in Gyre Therapeutics in Q2 2018 and held it in 2 quarters.
  • FNY Investment Advisers's Gyre Therapeutics position peaked at $43K in Q3 2018.
  • 65 funds tracked by Wall St. Rank held Gyre Therapeutics as of Q4 2018.

Based on FNY Investment Advisers's 13F filing for Q4 2018, filed 22 Jan 2019.